L'intérêt à découvert pour IGM Biosciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de IGM Biosciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

IGM Biosciences (NASDAQ:IGMS) Stock, Rapport sur les intérêts à découvert

IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

IGM Biosciences Inc

News

Offerings

BTAI

BioXcel Therapeutics Files For Resale Of Up To 5.1M Shares By The Selling Stockholders

GrafTech International Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) ("GrafTech" or the "Company") today announced that it has entered into a cooperation agreement (the "Cooperation Agreement") with one of the Company's largest stockholders, Mr. Nilesh Undavia, who owns approximately 6.7% of the Company's outstanding common stock.
Pursuant to the Cooperation Agreement, GrafTech has appointed Sachin Shivaram to the Board of Directors of the Company (the "Board"), effective immediately. Additionally, GrafTech and Mr. Undavia will work together to identify a mutually agreed upon independent candidate to nominate for election to the Board at the 2025 annual meeting of stockholders of the Company (the "2025 Annual Meeting"), although if the parties are unable to find a mutually agreeable candidate in time for inclusion on the ballot of the 2025 Annual Meeting, they will continue to work together to find a mutually agreeable candidate to be appointed as a director on the Board.

Management

GrafTech Enters Cooperation Agreement With Stakeholder Nilesh Undavia, Owning 6.7%, Appoints Sachin Shivaram To Board, Seeks Independent Candidate For 2025 Board Election

On January 10, 2025, Mawson Infrastructure Group Inc. ("Mawson" or "the Company"), filed its answer ("the Filing"), attached herein as an Exhibit, to the involuntary petition against the Company (the "Petition") pursuant to 11 U.S.C. § 303(a) filed on December 4, 2024 by W Capital Advisors Pty Ltd, Marshall Investments MIG Pty Ltd, and Rayra Pty Ltd, all of whom are Australian entities (the "Petitioners"). Mawson had previously announced in a filing on Form 8-K issued on December 4, 2024, that the Company's Board of Directors intended to vigorously defend the Company against the Petition filed by these Australian entities.
&nbsp;
As per the Company's most recent 10-Q filing on November 14, 2024, W Capital Advisors Pty Ltd as trustee for the W Capital Advisors Fund and Marshall Investments MIG Pty Ltd as trustee for the Marshall Investments MIG Trust had filed proceedings in Australia, and the Company believes that these entities were using such proceedings in an improper attempt to gain leverage in ongoing legal disputes between the parties. The Company believes that the filing of this Involuntary Petition is an extension of the ongoing disputes, including with James Manning, the Company's former Board Director and Officer, and a continuation of the pattern of bad faith actions, by James Manning and the Petitioners, with the improper intention of harassing and intimidating Mawson.
&nbsp;
The Company's counsel plans to propound discovery requests to the Petitioners. In addition, James Manning remains the subject of an investigation by the Company's Audit Committee, including related to his dealings with W Capital Advisors Pty Ltd as trustee for the W Capital Advisors Fund – among several other matters – including current litigation with an entity related to James Manning, Vertua Property Inc. ("Vertua"), regarding alleged self-dealing, breach of contract, and tortious interference with a business relationship.
&nbsp;
The Company had previously reported through an 8-K filing on March 29, 2024, that it may seek to exit certain or all of its entities and holdings in Australia. The Company currently operates facilities in the United States of America and does not have any operating sites or assets in Australia.
&nbsp;
The Company continues to also pursue its complaint filed in The Court of Common Pleas of Mercer County, Pennsylvania (file number 2024-2332) on October 17, 2024 against Vertua as landlord for the Company's Sharon, PA property for breach of the lease agreement and wrongful termination of the lease, as well as for tortious interference with a business relationship. The Company is seeking reinstatement of the lease, compensatory damages, disgorgement of revenue, and exemplary and punitive damages, as well as reimbursement for its costs and litigation expenses. Vertua is a company not only related to James Manning, but also affiliated with Darron Wolter of W Capital Advisors Pty Ltd as trustee for the W Capital Advisors Fund.
&nbsp;
Mawson expects to vigorously pursue sanctions, attorney fees, general and punitive damages against the Petitioners, as available to the full extent of the law

Legal

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

Mawson Files Answer To Involuntary Petition By Australian Entities, Alleging Bad Faith Actions And Intimidation; Investigates Former Director James Manning; Pursues Legal Action Against Vertua In PA For Breach, Seeks Sanctions and Damages; May Exit Australia Holdings

NNN Reit Says Kevin B. Habicht To Retire As EVP And CFO; Vincent H. Chao To Assume CFO Role On April 1, 2025

SOAR

Volato Group Says Two Breach Of Contract Complaints Were Filed Against Co In Nov 2024, Related To Transition Of Co's Fleet Management To FLYX; Says Co Will Vigorously Defend Both Matters

XChange TEC.INC Say Yong Zhang Resigned As CEO And Chairman Of Board

Contracts

AIXI

XIAO-I Entered Into Two Securities Purchase Agreements To Issue, Sell Two Convertible Promissory Notes Of $4.6M

Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) just disclosed its Q1 earnings on Friday, January 10, 2025 at 02:19 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Lexaria Bioscience missed estimated earnings by -33.0%, reporting an EPS of $-0.16 versus an estimate of $-0.12.
Revenue was up $32 thousand from the same period last year.
<h3>Earnings History Overview</h3>
During the previous quarter, the company missed on EPS by $0.04, leading to a 2.0% drop share price change the next day.

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Lexaria Bioscience <a href="https://www.benzinga.com/quote/LEXX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

LEXX

Lexaria Bioscience Earnings Analysis: Q1 Recap

Accolade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) released its Q3 earnings on Friday, January 10, 2025 at 09:30 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Accolade missed estimated earnings by -87.0%, reporting an EPS of $-0.3 versus an estimate of $-0.16.
Revenue was up $5.69 million from the same period last year.
<h3>Historical Earnings Summary</h3>
Last quarter the company beat on EPS by $0.14 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Accolade's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.44</td>
<td>-0.48</td>
<td>-0.07</td>
<td>-0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.30</td>
<td>-0.35</td>
<td>-0.10</td>
<td>-0.28</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>105.01M</td>
<td>105.19M</td>
<td>123.91M</td>
<td>96.24M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>106.36M</td>
<td>110.47M</td>
<td>124.83M</td>
<td>99.37M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Accolade <a href="https://www.benzinga.com/quote/ACCD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCD

Accolade Q3 Earnings Assessment

Electric vehicle company Faraday Future Intelligent Electric Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) was one of the many companies that presented or showed off new products, concepts and company growth initiatives at the<a href="https://www.benzinga.com/25/01/42775636/ces-2025-preview-nvidia-amd-in-spotlight-other-trends-and-stocks-to-watch"> 2025 CES conference.</a>
An electric vehicle media outlet is skeptical of the company's latest plan for growth.
What Happened: When it comes to Faraday Future, the company has focused on the premium <a href="https://www.benzinga.com/electric-vehicles">electric vehicles sector</a> with the FF 91 having a cost of more than $300,000.
The company now plans to grow with its new Faraday X sub-brand and have vehicles priced in the $20,000 to $50,000, executives told <a href="https://insideevs.com/news/746781/faraday-x-ceo-interview/">InsideEVs </a>at CES.
Faraday plans to have the FX 5 and FX 6 vehicles priced from $20,000 to $30,000 and $30,000 to $50,000 respectively and the Super One minivan with a current undetermined price as the next models for growth.
A Super One prototype was at CES and Faraday X CEO Max Ma highlighted the company's excitement for this luxury passenger van.
Ma called the vehicle the "Nokia and iPhone moment" for Faraday Future saying, "You have the right product and open people's hearts."
Ma said the Super One will serve the market between high-end minivans and super-luxury SUVs, adding that it will transform the market.
"Today, the celebrities are using Escalades. Big, but there's no real luxury, top luxury, or you know, space and comfort. There's no AI. And then if you want to drive yourself, it's very hard to drive," Ma told InsideEVs.
Focusing on growth through AI, Ma also referred to the Super One as a "luxury AI MPV."
The prototype shown to the media highlighted the fact that Faraday has partnered with a Chinese company to make the Super One.
"Essentially, the Super One will be a rebadged Chinese plug-in hybrid MPV, with FF's tech," InsideEVs said.
The writer said the vehicle looked simply like a Chinese MPV and had no AI features.
Read Also: <a href="https://www.benzinga.com/news/small-cap/25/01/42893897/faraday-futures-fx-6-to-target-30k-50k-price-range-with-ai-driven-ev-tech-details">Faraday Future&#8217;s FX 6 To Target $30K-$50K Price Range With AI-Driven EV Tech</a>
Why It's Important: Faraday Future has struggled since announcing <a href="https://www.benzinga.com/m-a/21/01/19367501/faraday-future-going-public-via-spac-what-investors-should-know">a SPAC merger back </a>in 2021.
The merger announcement came with a value of $3.4 billion for the company. Fast forward to today and Faraday Future has a market capitalization of $94 million and an enterprise value of $203 million.
Shares are down 92% over the last year and down 43% year-to-date in 2025 already.
The appearance and prototype at CES could help restore brand awareness and trust in the company after several controversies and failures along the way. Top of Form
"We have been trained, with big hearts, with resilience, with hard (work). We also want to have this big opportunity to prove that we can do it again, right?" Ma told InsideEVs.
Ma noted the company is looking for a fresh start of sorts, which Faraday X could be the centerpiece of.
The CES presentation and media interview could cause some confusion with the company highlighting its focus on cheaper electric vehicles and showing off and naming a luxury multi-person vehicle as growth items.
FFIE Price Action: Faraday Future stock trades at $1.56 at market close Friday versus a 52-week trading range of $0.99 to $155.60.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41541997/revving-up-in-the-middle-east-faradays-new-uae-headquarters-solidifies-ev-expansion-strategy">Revving Up In The Middle East: Faraday&#8217;s New UAE Headquarters Solidifies EV Expansion Strategy</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Global

Tech

Trading Ideas

FFIE

Faraday Future Highlights Faraday X: Here's What The EV Company Is Banking On After Stock Fell 90% In Past Year

BLKB

Blackbaud Files For Mixed Shelf Offering; Size Not Disclosed

Wall Street wiped out its entire post-election rally this week as mounting interest-rate fears were stoked by a red-hot labor market, surging inflation expectations and escalating geopolitical tensions ahead of Donald Trump&#8216;s <a href="https://www.benzinga.com/news/25/01/42916780/donald-trump-receives-unconditional-discharge-in-new-york-hush-money-case-will-enter-white-house-as-convicted-felon">return to the White House</a>. 
In a shortened trading week due to Thursday&#8217;s funeral for former President Jimmy Carter, market activity reached a<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42922299/wall-street-tumbles-on-blowout-payrolls-oil-rallies-to-76-us-dollar-hits-26-month-highs-whats-driving-markets-friday"> fever pitch on Friday.</a>
The U.S. economy boasted an impressive <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42912480/us-economy-adds-256000-payrolls-in-december-as-tight-labor-market-tops-forecasts-dollar-treasury-yields-spike">256,000 nonfarm payrolls</a> in December — a figure that made the consensus economist forecast of 160,000 jobs pale in comparison. This marked the strongest employment growth since March. Additionally, the unemployment rate dropped to 4.1%, beating forecasts of 4.2%.
In simple terms, the U.S. labor market ended 2024 firing on all cylinders. While this robust performance bodes well for consumer spending, it poses a significant challenge for the Federal Reserve, which now faces mounting pressure to <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42913622/dollar-soars-to-27-month-highs-30-year-yields-hit-5-stocks-tumble-jobs-report-oil-spike-darken-feds-interest-rate-cut-hopes">keep inflation in check.</a>
Expectations for a new interest rate cut were further pushed down the road to September 2025 in reactions to new economic developments. For stocks, this represented a setback, as indices tumbled across the board.
Earlier in the week, President-elect Trump, in a one-hour speech at Mar-a-Lago, floated provocative ideas, including annexing <a href="https://www.benzinga.com/news/events/25/01/42860583/trump-floats-canada-as-51st-us-state-says-hes-ready-to-use-economic-force-to-achieve-it">Canada as a 51st state</a>, imposing stringent tariffs on Mexico and demanding NATO members increase military spending to 5% of GDP.
On Friday, the Biden administration announced <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/42919047/oil-nears-80-as-us-prepares-new-russia-sanctions">new sanctions targeting Russian oil </a>giants Gazprom Neft and Surgutneftegas, shadow fleet vessels and opaque traders. These measures triggered a sharp rise in oil prices, further unsettling markets.
<h3 class="wp-block-heading">Inflation Fears Surge</h3>
Consumer inflation expectations for the next five years reached 3.3% in January 2025, hitting their highest levels since June 2008, according to <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42917321/consumer-inflation-worries-highest-since-2008-u-of-m-survey-says-wall-street-tumbles-to-2-month-lows">a University of Michigan survey</a>. Rising inflation anxiety may reflect concerns over the incoming Trump administration&#8217;s planned tariff hikes.
<h3 class="wp-block-heading">Wildfires Impact Insurers</h3>
California wildfires destroyed over 10,000 structures, intensifying pressure on property insurers like Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) and Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>). Economic losses could reach $57 billion, with insurance <a href="https://www.benzinga.com/markets/equities/25/01/42906089/california-wildfires-ignite-concerns-for-insurance-stocks-here-are-some-insurance-etfs-which-could-be-impacted">stocks under market focus.</a>
<h3 class="wp-block-heading">Rate Hike Panic</h3>
The blowout December jobs report forced Bank of America Securities to scrap expectations for further interest-rate cuts. It marks a notable U-turn from a top investment bank. Economist Aditya Bhave floated the risk of rising discussions towards interest rate cuts, should core inflation <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42926956/bank-of-america-scraps-interest-rate-cut-calls-betting-markets-go-haywire-as-hiking-panic-mounts">surges above 3% again. </a>
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42925767/palantirs-nasdaq-100-hype-fades-as-stock-sinks-post-inclusion">Palantir&#8217;s Nasdaq-100 Hype Fades As Stock Sinks 15% Post-Inclusion</a></li>
</ul>
Image: Shutterstock

Analyst Color

Government

Large Cap

Macro Economic Events

Regulations

Economics

Federal Reserve

US Labor Market Smashes Expectations, Wall Street Erases Post-Election Rally As Interest Rate Anxiety Grows: This Week In The Markets

Raytech Holding Limited (the "Company" or "RAY"), a Hong Kong-headquartered company specializing in design, sourcing and wholesale of personal care electrical appliances for international brand owners, today announced its financial results for the six months ended September 30, 2024.
CHING Tim Hoi, CEO and Chairman of the Company, commented, "The Company achieved a notable 31.0% increase in revenue for the six months ended September 30, 2024, reaching HKD 43.2 million (US$ 5.6 million), up from HKD 33.0 million in the prior year. This growth was driven primarily by strong sales in our trimmer series within the personal care products segment, reflecting our success in attracting new customers."

Raytech 6-Month EPS $0.03; Revenue $5.56M

System1 Was Notified By The New York Stock Exchange That It Is Not In Compliance; Company Intends To Cure The Deficiency And Regain Compliance With NYSE

Boqii Holding Limited ("Boqii" or the "Company") (NYSE American:&nbsp;BQ) today announced that it will change its ratio of its American Depositary Shares ("ADSs") to Class A ordinary shares from one (1) ADS representing fifteen (15) Class A ordinary shares to one ADS&nbsp;representing one hundred and fifty&nbsp;(150) Class A ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become effective on or about January 21, 2025&nbsp;(U.S. Eastern Time) (the "ADS Ratio Change&nbsp;Effective Date").
For Boqii's ADS holders, the ADS Ratio Change will have the same effect as a 1-for-10 reverse split on the&nbsp;existing ADSs. Each ADS holder on the ADS Ratio Change Effective Date will be required on mandatory basis to surrender to The Bank of New York Mellon, as depositary, (the "Depositary") for Boqii's ADS program, every 10 old ADSs held in exchange for one new&nbsp;ADSs. No action is required by holders of&nbsp;uncertificated ADSs to effect the ADS Ratio Change as the change will be effected on the books of the Depositary.&nbsp;&nbsp;

Stock Split

Boqii Announces ADS Ratio Change From 1 ADS Representing 15 Class A Ordinary Shares To 1 ADS Representing 150 Class A Ordinary Shares, Effective On Or About January 21, 2025

Politics

General

President Biden To Deliver Farewell Address From Oval Office On Wednesday At 8:30 p.m. ET

HTLF

UMBF

UMB Financial Corp Receives Regulatory Approval To Acquire Heartland Financial USA

Rexford Industrial Realty, Inc. (the "Company" or "Rexford Industrial") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>), a real estate investment trust focused on creating value by investing in and operating industrial properties located throughout infill Southern California,&nbsp;today reports no damage to its properties and does not anticipate unfavorable impacts to the Company's operating results or financial condition due to the wildfires in Los Angeles County.

REXR

Rexford Industrial Reports No Impacts To Business From The Wildfires In Los Angeles County

VRDN

Viridian Therapeutics Appoints Seth Harmon As CFO

VTAK

Catheter Precision Files For Mixed Shelf Of Up To $20M

Guggenheim downgraded IGM Biosciences (IGMS) to Neutral from Buy. Published first on TheFly – the ultimate source for real-time, market-moving brea...

IGM Biosciences downgraded to Neutral from Buy at Guggenheim

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on IGM Biosciences (IGMS – Research Report) and Abiva...

Analysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Abivax SA Sponsored ADR (ABVX)

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – Constellation Energy&nbsp;(CEG) up 13% after entering an...

Morning Movers: Constellation Energy climbs following deal to buy Calpine

Biggest stock movers Friday: TLRY, DAL, MVST, and more

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

AMD downgraded, Nike upgraded: Wall Street's top analyst calls

Truist analyst Asthika Goonewardene lowered the firm's price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the shares....

IGM Biosciences price target lowered to $2 from $12 at Truist

IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company's sha...

Jefferies downgrades IGM Biosciences (IGMS) to a Hold

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical ...

IGM Biosciences downgraded to Hold from Buy at Jefferies

IGM Bio plunges as Wall Street downgrades on portfolio shakeup

IGM Biosciences Stock: Bad News With No Turnaround In Sight

ABVX

ACHR

APPF

CART

GILD

HIMS

IGMS

JOBY

MVST

NWSA

NXPI

PENG

PINS

RKLB

ROKU

SHOP

SNYNF

TLRY

Press Releases

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Treatment.com AI Inc. (TRUE.CN) Advances AI in Healthcare with Strategic Moves

Health Care

IGM Biosciences to Present at the Jefferies Healthcare Conference

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

IGM Biosciences to Present at Three Upcoming Investor Conferences

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

AKTS

BNED

CSE:TRUE

GWAV

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Nuvalent

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

PTC Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

United Therapeutics Corporation - Common Stock

United Therapeutics

Veracyte

Viking Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

IGM Biosciences

Intérêt court

IGM Biosciences (NASDAQ:IGMS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL